EUVIMED · CrossrefZeitschrift
npj Breast Cancer
ISSN 2374-4677 · Springer Science and Business Media LLC
Neueste Artikel
Nucleotide excision repair deficiency identified by mutational signatures is associated with cisplatin response in triple-negative breast cancer
Hypermethylation in CpG-rich cfDNA fragments enables accurate detection of circulating tumor DNA in BRCA1- and BRCA2-associated breast and ovarian cancer
First-line CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer with chronic kidney disease stage 3b–5: a target trial emulation
Genomic characterization of ER-positive primary tumors and corresponding relapses identifies potentially targetable alterations
AI-derived tumor-infiltrating lymphocytes enhance the prediction of pathologic complete response in early-stage triple-negative breast cancer
Beyond a single disease: review of rare histological subtypes of triple-negative breast cancer with implications for prognosis and treatment
Differential response and survival across rare histologic subtypes of triple-negative breast cancer following neoadjuvant chemo-immunotherapy
Immune landscape in PD-L1- and TROP2-positive triple-negative breast cancer
Validation of pathology-based triage for the 21-gene recurrence score: a meta-analysis and qualitative synthesis of the Magee equations
The WinPro trial: window-of-opportunity study of endocrine therapy with micronised progesterone in ER-positive breast cancer
Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity in ERα+ breast cancer
Ensemble machine learning for predicting breast cancer recurrence and mortality using clinical and hemogram data
Impact of neoadjuvant chemotherapy on local breast microbiota and macrophages in ER-positive breast cancer with links to treatment response
Targeted axillary dissection in breast cancer patients: a systematic review and meta-analysis
Acute circulating tumor DNA dynamics during and after systemic therapy initiation for advanced triple-negative breast cancer
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry
Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutation
Identification of racial disparities across MammaPrint and BluePrint subtypes in HR + HER2- breast cancer
RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer
Programmable local immunochemotherapy for triple-negative breast cancer via spatiotemporally controlled release of CpG oligodeoxynucleotides, gemcitabine, and paclitaxel
JAK/STAT1-interferon-ISGylation networks in breast cancer resistance to inhibitors of FOXM1 and CDK4/6
Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane
Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer
Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial
Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology
Co-delivery of chemokine CXCL9 and costimulatory ligand TNFSF9 by mesenchymal stem cells reprograms the immune microenvironment for triple-negative breast cancer
Racial differences in biomarkers, treatment, and outcomes in HR+/HER2- metastatic breast cancer in the United States
Host-derived interleukin-1α drives tumor immunosuppression by reprogramming tumor-associated myeloid cells
Racial disparity in pro-metastatic tumor microenvironment in treatment naïve breast cancer
Tractable mouse TNBC models capture the heterogeneous tumor immune microenvironment and adaptation to PD-L1 blockade
EUVIMED